Targeting the CD47-SIRPα axis continues to show promise in solid tumours
In early-phase studies, two novel agents showed low propensity to induce heamatological toxicities in heavily pre-treated solid tumours
Exploiting HER2 tumour heterogeneity with digital oncology
Multi-regional modelling reveals new ways to personalise treatments in gastric and breast cancers
First-line dual targeting combination shows encouraging, durable responses in triple-negative breast cancer
A manageable safety profile was also reported for pumitamig plus the antibody-drug conjugate DB-1305/BNT325 in an early-phase study
Optimal sequencing of immunotherapy in MSI-H/dMMR colon cancer remains uncertain
In light of recent evidence from the ATOMIC trial, balancing adjuvant and neoadjuvant immunotherapy approaches continues to challenge clinical decision-making.
How to sequence antibody–drug conjugates in metastatic breast cancer? Target switching alone may not be the answer
The first prospective phase II trials evaluating TOPO1 ADC after prior TOPO1 ADC therapy confirm the emergence of cross-resistance
SERD therapy demonstrates robust anti-proliferative activity in young patients with ER-positive/HER2-negative early breast cancer
Encouraging results with giredestrant support the future use of SERD-based endocrine strategies in this setting
Counting lines of therapy counts: ESMO leads the way of standardisation
A new ESMO consensus-driven document provides definitions, formats and minimum required data to uniform enumeration and reporting of prior lines of therapy across solid tumours
Novel emerging targets, new treatment opportunities
Drug development in oncology is increasingly moving towards integrated strategies that consider tumour cells, their microenvironment and anatomical context
Overcoming resistance to immunotherapy in NSCLC?
Understanding the evolution of immunotherapy resistance holds the key to developing novel strategies in NSCLC
CTLA-4 targeting leads to improved overall survival in NSCLC progressing on immunotherapy
Early phase III trial results signal a much-needed chemotherapy-free advance with gotistobart in a setting where therapeutic choices are limited